ReviewJournal of hematology & oncology2022
Tumor organoids: applications in cancer modeling and potentials in precision medicine.
Review in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
188 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- [Application and Progress of Organoid-on-a-chip Platforms in Lung Cancer Diagnosis and Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Pooled it
- Vascularised organoids: Recent advances and applications in cancer research.Clinical and translational medicine · 2025Pooled it
- Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026Review
- Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.Human vaccines & immunotherapeutics · 2026Article
- New approach methodologies in nanomedicine: bridging the gap betweenChemical Society reviews · 2026Review
- Tumor microenvironment-simulated organoids for personalized therapy prediction in head and neck squamous cell carcinoma.Oncogene · 2026Article
- Review
- Development and validation of a model for predicting central lymph node metastasis in colorectal cancer based on CT textural features and clinical indicators.Translational cancer research · 2026Article
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- AI-Guided Long Non-Coding RNA Target Discovery for Precision Medicine: Integrating GWAS, Multi-Omics, Experimental Validation, and RNA Therapeutics.Biomedicines · 2026Review
- The Application of 3D Cell Culture in Thyroid Cancer.Annals of biomedical engineering · 2026Review
- Antitumor effects of the novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.Journal of translational medicine · 2026Article
- Radioluminescence microscopy of tumor organoids enabled by a reconfigurable high-resolution imaging setup.EJNMMI research · 2026Article
- ANGPTL4 contributes to osimertinib resistance through NDRG1-associated extracellular matrix remodeling in EGFR-mutant NSCLC organoid models.Cancer cell international · 2026Article
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Organoid technology in cancer research.Molecular biomedicine · 2026Review
- Quantitative Cellular AGing Evaluation system (qCAGEs): a dual-parameter platform for high-throughput senescence screening.GeroScience · 2026Article
- Cell Line-Dependent Effects of Spheroid Formation Method on Drug Response in Melanoma Models.Cells · 2026Article
- Organoid models: Regulations and prospects for the development of investigational new drugs.Chinese medical journal · 2026Review
128 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer is a top-ranked life-threatening disease with intratumor heterogeneity. Tumor heterogeneity is associated with metastasis, relapse, and therapy resistance. These factors contribute to treatment failure and an unfavorable prognosis. Personalized tumor models faithfully capturing the tumor heterogeneity of individual patients are urgently needed for precision medicine. Advances in stem cell culture have given rise to powerful organoid technology for the generation of in vitro three-dimensional tissues that have been shown to more accurately recapitulate the structures, specific functions, molecular characteristics, genomic alterations, expression profiles, and tumor microenvironment of primary tumors. Tumoroids in vitro serve as an important component of the pipeline for the discovery of potential therapeutic targets and the identification of novel compounds. In this review, we will summarize recent advances in tumoroid cultures as an excellent tool for accurate cancer modeling. Additionally, vascularization and immune microenvironment modeling based on organoid technology will also be described. Furthermore, we will summarize the great potential of tumor organoids in predicting the therapeutic response, investigating resistance-related mechanisms, optimizing treatment strategies, and exploring potential therapies. In addition, the bottlenecks and challenges of current tumoroids will also be discussed in this review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.